Oncologic Outcomes of Patients With Resected T3N0M0 Non-small Cell Lung Cancer

医学 危险系数 内科学 置信区间 比例危险模型 多元分析 肺癌 肿瘤科 回顾性队列研究 胃肠病学
作者
Edouard Marques,Kevin F. Kennedy,Dorothy J. Giroux,Vanessa B. Cilento,Katherine K. Nishimura,Wentao Fang,Paula Ugalde Figueroa
出处
期刊:Seminars in Thoracic and Cardiovascular Surgery [Elsevier BV]
被引量:1
标识
DOI:10.1053/j.semtcvs.2022.08.007
摘要

In the eighth edition TNM staging, the T3N0M0 category represents a heterogeneous group of non-small cell lung cancers (NSCLC). This study aims to compare the oncologic outcomes associated with individual T3 features. We performed a single-institution, retrospective analysis of 280 consecutive patients with pT3N0M0 NSCLC. Multivariate regression models were used to estimate associations of clinical factors with oncologic outcomes. The patients were grouped according to their T3 features into 4 prognostic groups: chest wall infiltration (CWI-PG), largest diameter >5 cm and ≤7 cm (Size-PG), presence of a satellite nodule (SN-PG), and all other T3 features. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier and Cox proportional hazard analyses. Tumors were most often classified as T3N0M0 by size (156 patients, 55.7%), and the highest rate of incomplete resection occurred in patients with CWI (n = 7, 25.9%). In multivariate analysis, CWI (hazard ratio [HR] 2.45, 95% confidence interval [CI] 1.36, 4.44), incomplete resection (HR 3.01, 95% CI 1.29, 7.05), and age >65 (HR 1.6; 95% CI 1.08, 2.38) were independently associated with worse OS, and female sex was associated with better OS (HR 0.6, 95% CI 0.42, 0.87). The CWI-PG had poorer OS when compared with each of the other prognostic groups (P < 0.05), and the Size-PG had inferior OS when compared with the SN-PG (P = 0.039). This single-center study demonstrated significant differences in OS and PFS between patients with different T3 classifying features and suggest that further subdivision of the T3 category should be considered. In the eighth edition TNM staging, the T3N0M0 category represents a heterogeneous group of non-small cell lung cancers (NSCLC). This study aims to compare the oncologic outcomes associated with individual T3 features. We performed a single-institution, retrospective analysis of 280 consecutive patients with pT3N0M0 NSCLC. Multivariate regression models were used to estimate associations of clinical factors with oncologic outcomes. The patients were grouped according to their T3 features into 4 prognostic groups: chest wall infiltration (CWI-PG), largest diameter >5 cm and ≤7 cm (Size-PG), presence of a satellite nodule (SN-PG), and all other T3 features. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier and Cox proportional hazard analyses. Tumors were most often classified as T3N0M0 by size (156 patients, 55.7%), and the highest rate of incomplete resection occurred in patients with CWI (n = 7, 25.9%). In multivariate analysis, CWI (hazard ratio [HR] 2.45, 95% confidence interval [CI] 1.36, 4.44), incomplete resection (HR 3.01, 95% CI 1.29, 7.05), and age >65 (HR 1.6; 95% CI 1.08, 2.38) were independently associated with worse OS, and female sex was associated with better OS (HR 0.6, 95% CI 0.42, 0.87). The CWI-PG had poorer OS when compared with each of the other prognostic groups (P < 0.05), and the Size-PG had inferior OS when compared with the SN-PG (P = 0.039). This single-center study demonstrated significant differences in OS and PFS between patients with different T3 classifying features and suggest that further subdivision of the T3 category should be considered. T3N0M0 NSCLC Subtypes - A Signal for Disparate Outcomes after SurgerySeminars in Thoracic and Cardiovascular SurgeryPreviewThe 8th edition of the TNM staging system for non-small cell lung cancer (NSCLC) was a leap forward from prior versions in stratifying the T-stage of small tumors.1 However, certain categories still remain more ambiguous than desired. The T3N0M0 stage (IIb) has been encompassing a heterogeneous group of locally advanced tumors with a variety of T3 defining features - namely, larger size (5-7 cm), invasion into some structures, and separate and/or ”satellite” nodules in the same lobe. Tumors with any of the T3 descriptors may be still amenable for a complete resection, which is the common ground for this stage, but the different features may also confer a disparate biologic behavior that could define their prognosis after surgery. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无花果应助Jojo采纳,获得10
1秒前
2秒前
2秒前
2秒前
温柔银耳汤完成签到,获得积分10
2秒前
CY关闭了CY文献求助
3秒前
4秒前
徐不想搞科研完成签到,获得积分10
5秒前
奥利奥发布了新的文献求助30
5秒前
悦耳绿草发布了新的文献求助10
6秒前
yinyin发布了新的文献求助10
8秒前
8秒前
123发布了新的文献求助10
8秒前
李亚初发布了新的文献求助10
8秒前
10秒前
10秒前
CT发布了新的文献求助10
11秒前
iNk应助DrDong98采纳,获得20
12秒前
lxxy完成签到,获得积分10
12秒前
热孜宛古丽完成签到,获得积分10
13秒前
悦悦完成签到,获得积分10
14秒前
科研通AI2S应助123采纳,获得10
15秒前
Vivi发布了新的文献求助10
16秒前
车轮滚滚发布了新的文献求助10
16秒前
Subatom完成签到,获得积分10
17秒前
不倦应助热孜宛古丽采纳,获得10
19秒前
yuliuism完成签到,获得积分10
21秒前
共享精神应助奥利奥采纳,获得30
22秒前
pluto应助莉莉采纳,获得10
22秒前
车轮滚滚完成签到,获得积分10
23秒前
尼古丁真应助CT采纳,获得10
23秒前
Owen应助123采纳,获得10
24秒前
上官若男应助lmm采纳,获得10
25秒前
不安青牛应助清风何解忧采纳,获得10
27秒前
28秒前
可爱的函函应助清风如月采纳,获得10
29秒前
卡牌大师完成签到,获得积分10
29秒前
30秒前
放青松完成签到,获得积分10
31秒前
lmm发布了新的文献求助10
31秒前
高分求助中
(应助此贴封号)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
F-35B V2.0 How to build Kitty Hawk's F-35B Version 2.0 Model 2500
줄기세포 생물학 1000
The Netter Collection of Medical Illustrations: Digestive System, Volume 9, Part III - Liver, Biliary Tract, and Pancreas (3rd Edition) 600
INQUIRY-BASED PEDAGOGY TO SUPPORT STEM LEARNING AND 21ST CENTURY SKILLS: PREPARING NEW TEACHERS TO IMPLEMENT PROJECT AND PROBLEM-BASED LEARNING 500
2025-2031全球及中国蛋黄lgY抗体行业研究及十五五规划分析报告(2025-2031 Global and China Chicken lgY Antibody Industry Research and 15th Five Year Plan Analysis Report) 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4475552
求助须知:如何正确求助?哪些是违规求助? 3933808
关于积分的说明 12205203
捐赠科研通 3588454
什么是DOI,文献DOI怎么找? 1972940
邀请新用户注册赠送积分活动 1010610
科研通“疑难数据库(出版商)”最低求助积分说明 904210